Mallinckrodt Accents Critical Care With Ikaria Acquisition

Published on: 

Mallinckrodt Pharmaceuticals has bought Ikaria, a privately-held critical care company, for $2.3 billion.


Mallinckrodt Pharmaceuticals, a specialty biopharmaceutical company, has inked a deal for $2.3 billion with Ikaria, a privately-held critical care company focused on the development and commercialization of innovative
therapies and delivery systems. The deal is expected to increase Mallinckrodt's net sales by $150 million.

Ikaria's leading product, FDA-approved Inomax, is a vasodilator that is designed for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure, in conjuction with ventilatory support and
other treatments. Inomax improves oxygenation and reduces the need for extracorporeal membrane oxygenation and is specifically indicated for patients experiencing hypoxic respiratory failure associated with clinical
or endocardiographic evidence of pulmonary hypertension, according to a press release.


Source: Mallinckrodt